Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
$11.45
-2.6%
$13.29
$10.45
$21.69
$4.05B0.58651,566 shs88,875 shs
CONMED Co. stock logo
CNMD
CONMED
$59.22
-1.4%
$55.94
$46.00
$78.58
$1.83B1.19451,221 shs34,541 shs
Glaukos Co. stock logo
GKOS
Glaukos
$92.46
+0.1%
$94.30
$77.10
$163.71
$5.27B0.83682,011 shs117,359 shs
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€23.69
-3.0%
€21.30
€16.56
€24.96
$7.17B0.51347,557 shs43,694 shs
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
-0.38%+8.77%+4.13%-27.95%-19.81%
CONMED Co. stock logo
CNMD
CONMED
-1.10%+7.34%+16.20%-3.59%-17.46%
Glaukos Co. stock logo
GKOS
Glaukos
-2.49%+5.39%+2.40%-35.88%-14.97%
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
+3.30%+14.97%+11.86%+21.92%+8.10%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
4.3036 of 5 stars
4.14.00.00.02.60.03.8
CONMED Co. stock logo
CNMD
CONMED
4.1621 of 5 stars
1.23.02.54.32.70.83.1
Glaukos Co. stock logo
GKOS
Glaukos
4.6847 of 5 stars
4.42.00.04.44.12.50.6
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
1.0168 of 5 stars
0.01.01.70.02.70.01.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
2.25
Hold$15.5035.36% Upside
CONMED Co. stock logo
CNMD
CONMED
2.40
Hold$62.205.04% Upside
Glaukos Co. stock logo
GKOS
Glaukos
2.75
Moderate Buy$134.6745.65% Upside
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
2.86
Moderate BuyN/AN/A

Current Analyst Ratings Breakdown

Latest CNMD, STVN, BLCO, and GKOS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/6/2025
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$18.00 ➝ $12.00
5/6/2025
Glaukos Co. stock logo
GKOS
Glaukos
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$110.00 ➝ $72.00
5/2/2025
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$20.00 ➝ $15.00
5/2/2025
Glaukos Co. stock logo
GKOS
Glaukos
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$140.00 ➝ $115.00
5/1/2025
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$14.00 ➝ $13.00
5/1/2025
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$15.00 ➝ $12.00
5/1/2025
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$19.00 ➝ $15.50
5/1/2025
CONMED Co. stock logo
CNMD
CONMED
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$70.00 ➝ $58.00
5/1/2025
CONMED Co. stock logo
CNMD
CONMED
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$70.00 ➝ $57.00
5/1/2025
CONMED Co. stock logo
CNMD
CONMED
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$91.00 ➝ $61.00
5/1/2025
Glaukos Co. stock logo
GKOS
Glaukos
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$140.00 ➝ $135.00
(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
$4.83B0.84$1.36 per share8.41$18.57 per share0.62
CONMED Co. stock logo
CNMD
CONMED
$1.32B1.39$6.49 per share9.13$31.15 per share1.90
Glaukos Co. stock logo
GKOS
Glaukos
$404.52M13.06N/AN/A$9.46 per share9.77
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
$1.10B6.50€0.99 per share23.97€4.15 per share5.71
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
-$317M-$1.03N/A11.930.85-6.62%3.35%1.66%7/30/2025 (Estimated)
CONMED Co. stock logo
CNMD
CONMED
$132.42M$3.8013.9811.681.8310.13%14.31%5.64%7/30/2025 (Estimated)
Glaukos Co. stock logo
GKOS
Glaukos
-$134.66M-$2.37N/AN/AN/A-39.04%-16.53%-10.61%7/30/2025 (Estimated)
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
$157.62M€0.5150.4040.847.1810.47%9.86%5.79%N/A

Latest CNMD, STVN, BLCO, and GKOS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/30/2025Q1 2025
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
$0.03-$0.07-$0.10-$0.60$1.15 billion$1.15 billion
4/30/2025Q1 2025
CONMED Co. stock logo
CNMD
CONMED
$0.81$0.95+$0.14$0.19$313.38 million$321.26 million
4/30/2025Q1 2025
Glaukos Co. stock logo
GKOS
Glaukos
-$0.33-$0.22+$0.11-$0.32$102.78 million$106.66 million
3/6/2025Q4 2024
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€0.20€0.20N/A€0.19€346.26 million€352.68 million
2/20/2025Q4 2024
Glaukos Co. stock logo
GKOS
Glaukos
-$0.38-$0.40-$0.02-$0.60$100.72 million$105.50 million
2/19/2025Q4 2024
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
$0.23$0.25+$0.02-$0.01$1.26 billion$1.28 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
N/AN/AN/AN/AN/A
CONMED Co. stock logo
CNMD
CONMED
$0.801.35%N/A21.05%N/A
Glaukos Co. stock logo
GKOS
Glaukos
N/AN/AN/AN/AN/A
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€0.060.25%N/A11.76%1 Years

Latest CNMD, STVN, BLCO, and GKOS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/2/2025
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
annual€0.060.3%6/5/20256/5/20257/17/2025
2/24/2025
CONMED Co. stock logo
CNMD
CONMED
quarterly$0.201.29%3/14/20253/14/20254/4/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
0.72
1.60
1.01
CONMED Co. stock logo
CNMD
CONMED
0.94
2.30
1.06
Glaukos Co. stock logo
GKOS
Glaukos
0.19
5.54
4.71
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
0.22
1.81
1.21

Institutional Ownership

CompanyInstitutional Ownership
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
11.07%
CONMED Co. stock logo
CNMD
CONMED
N/A
Glaukos Co. stock logo
GKOS
Glaukos
99.04%
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
N/A

Insider Ownership

CompanyInsider Ownership
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
0.76%
CONMED Co. stock logo
CNMD
CONMED
3.10%
Glaukos Co. stock logo
GKOS
Glaukos
5.80%
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
0.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
12,500353.37 million351.94 millionOptionable
CONMED Co. stock logo
CNMD
CONMED
4,10030.94 million28.81 millionOptionable
Glaukos Co. stock logo
GKOS
Glaukos
78057.14 million51.61 millionOptionable
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
4,650302.84 million300.72 millionOptionable

Recent News About These Companies

William Blair Forecasts Reduced Earnings for Stevanato Group

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bausch + Lomb stock logo

Bausch + Lomb NYSE:BLCO

$11.45 -0.31 (-2.63%)
As of 11:13 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

CONMED stock logo

CONMED NYSE:CNMD

$59.22 -0.84 (-1.39%)
As of 11:13 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. It markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. The company also provides battery-powered and autoclavable bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under Hall surgical brand name. In addition, it offers general surgery products, including clinical insufflation systems under AirSeal brand; smoke removal devices under Buffalo Filter brand; endomechanical products, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors used in minimally invasive surgeries; and electrosurgical solution comprising monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems and other accessories. Further, the company provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products for the treatment of diseases of the dilatation, hemostasis, biliary, structure management, and infection prevention and patient monitoring, including ECG and EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.

Glaukos stock logo

Glaukos NYSE:GKOS

$92.46 +0.10 (+0.11%)
As of 11:13 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Stevanato Group stock logo

Stevanato Group NYSE:STVN

€23.69 -0.73 (-2.99%)
As of 10:58 AM Eastern

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.